Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.
Original languageEnglish
Article number8905372
JournalCase Reports in Gastrointestinal Medicine
Volume2017
Number of pages3
ISSN2090-6528
DOIs
Publication statusPublished - 2017

Fingerprint

Sublingual Immunotherapy
Gastroesophageal Reflux
Heartburn
Pyroglyphidae
Gastrointestinal Contents
Oropharynx
Pruritus
Deglutition Disorders
Respiratory System
Immunotherapy
Nausea
Abdominal Pain
Esophagus
Vomiting
Diarrhea
Stomach
Acids

Bibliographical note

ISI Document Delivery No.: FI9UU Times Cited: 0 Cited Reference Count: 11 Juel, Jacob Juel, Jacob/0000-0002-4244-9047 0 1 Hindawi ltd London 2090-6536

Keywords

  • house-dust mite disease Gastroenterology & Hepatology

Cite this

@article{29d30329032946888f94f2f4e1fda859,
title = "Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy",
abstract = "Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.",
keywords = "house-dust mite disease Gastroenterology & Hepatology",
author = "J. Juel",
note = "ISI Document Delivery No.: FI9UU Times Cited: 0 Cited Reference Count: 11 Juel, Jacob Juel, Jacob/0000-0002-4244-9047 0 1 Hindawi ltd London 2090-6536",
year = "2017",
doi = "10.1155/2017/8905372",
language = "English",
volume = "2017",
journal = "Case Reports in Gastrointestinal Medicine",
issn = "2090-6528",
publisher = "Hindawi Publishing Corporation",

}

Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy. / Juel, J.

In: Case Reports in Gastrointestinal Medicine, Vol. 2017, 8905372, 2017.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy

AU - Juel, J.

N1 - ISI Document Delivery No.: FI9UU Times Cited: 0 Cited Reference Count: 11 Juel, Jacob Juel, Jacob/0000-0002-4244-9047 0 1 Hindawi ltd London 2090-6536

PY - 2017

Y1 - 2017

N2 - Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.

AB - Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.

KW - house-dust mite disease Gastroenterology & Hepatology

U2 - 10.1155/2017/8905372

DO - 10.1155/2017/8905372

M3 - Journal article

VL - 2017

JO - Case Reports in Gastrointestinal Medicine

JF - Case Reports in Gastrointestinal Medicine

SN - 2090-6528

M1 - 8905372

ER -